MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03814ntm a2200325 i 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
12102116 |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20211025124119.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
150118s2017 ua a f bm 000 0 eng | |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EG-EULC |
| Transcribing agency |
EG-EULC |
| Description conventions |
rda |
| 041 0# - LANGUAGE CODE |
|---|
| Language code of text/sound track or separate title |
eng |
| Language code of summary or abstract/overprinted title or subtitle |
ara |
| 082 04 - DEWEY DECIMAL CLASSIFICATION NUMBER |
|---|
| Classification number |
615.1 |
| Item number |
T.R.E |
| Edition number |
22 |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Taha, Raghda Talal Abd El-latif, |
| 9 (RLIN) |
33879 |
| Relator term |
author. |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Effects of Lorcaserin on Hypothalamo-Pituitary Ovarian Axis in Female Rats / |
| Statement of responsibility, etc |
Raghda Talal Abd El-latif Taha, (B.Sc. Pharmaceutical Sciences, Faculty of Pharmacy, Cairo University), supervision of Prof. Dr. Nabila N. M. El-Maraghy, (Head of Department of Pharmacology, Toxicology &Biochemistry, Faculty of Pharmaceutical Sciences and Pharmaceutical Industries, Future University), Dr. Sawsan A. Zaitone, (Assistant Professor of Pharmacology & Toxicology, Faculty of Pharmacy, Suez Canal University). |
| 246 15 - VARYING FORM OF TITLE |
|---|
| Title proper/short title |
تأثير لوركاسيرين على محور كل من المهاد و النخام و المبيض فى انثي الجرذان |
| 264 #1 - PUBLICATION, DISTRIBUTION, ETC. (IMPRINT) |
|---|
| Date of publication, distribution, etc |
2017 |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
135 pages, 4 pages : |
| Other physical details |
illustrations (some color) ; |
| Dimensions |
24 cm |
| 336 ## - CONTENT TYPE |
|---|
| Source |
rdacontent |
| Content type term |
text |
| 337 ## - MEDIA TYPE |
|---|
| Source |
rdamedia |
| Media type term |
unmediated |
| 338 ## - CARRIER TYPE |
|---|
| Source |
rdacarrier |
| Carrier type term |
volume |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Prof. Dr. Hesham Soliman Mohamed Soliman, (Professor of Pharmacognosy- Pharmacognosy Department- Vice Dean of Education and Student Affairs- Faculty of Pharmacy- Helwan University), Prof. Dr. Mariam Hussein Abd El Hameed Gonaid, (Professor of Pharmacognosy- Pharmacognosy Department- Faculty of Pharmacy, Cairo University, Future University In Egypt.), Dr. Reham Ragaei Ibrahim, (Lecturer of Pharmacognosy- Pharmacognosy Department- Faculty of PharmacyHelwan University). |
| 502 ## - DISSERTATION NOTE |
|---|
| Dissertation note |
Thesis (M.Sc.)-Suez Canal University, Faculty of pharmacy, Department of pharmacology and toxicology, 2017. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc |
Includes bibliographical references. |
| 520 3# - SUMMARY, ETC. |
|---|
| Summary, etc |
Renal allograft survival requires multiple immunosuppressive drugs. This strategy<br/>may lead to gastric complications that necessitate gastro-protective medications,<br/>notably, proton pump inhibitors (PPI). This study aimed to compare the influence<br/>of pantoprazole and esomeprazole on serum cyclosporine trough levels (C0) in<br/>renal transplant recipients (RTR). A prospective, parallel, open-label trial was<br/>conducted on 47 adult RTR receiving cyclosporine doses adjusted to attain trough<br/>concentrations of 100 to 150 μg/L, mycophenolate mofetil (MMF) 750 mg<br/>q12 hour and prednisolone at 5 mg daily at Nasser Institute, Cairo, Egypt from<br/>January to September 2016. Patients were randomized into the esomeprazole<br/>group (25) or pantoprazole group (22) receiving the same dose (40 mg once daily).<br/>The study outcomes included clinical signs of rejection and renal function<br/>decline, assessed by elevations in serum creatinine, caused by cyclosporine level<br/>variations in either of the two study groups. Renal function, C0 and CBC measurements were measured at baseline and monthly for 6 months. The mean C0<br/>values were higher in the pantoprazole group than in the esomeprazole group in<br/>the sixth month only (P = .007). Serum creatinine level was lower in the sixth<br/>month than at baseline in the esomeprazole group (P = .004). There were no<br/>signs of rejection biochemical or clinical in any of the study groups. In conclusion,<br/>PPIs should be used with caution and doses should be titrated to reach the C0 targets in RTR, which is of more importance in pantoprazole than esomeprazole to<br/>avoid C0 level elevation or decline affecting the allograft function |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
Text in English, abstracts in English and Arabic. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Pharmacology |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name as entry element |
Clinical pharmacology |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| Materials specified |
DSpace electronic resource |
| Uniform Resource Identifier |
<a href="http://dspace.fue.edu.eg/xmlui/handle/123456789/57">http://dspace.fue.edu.eg/xmlui/handle/123456789/57</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Thesis |
| Source of classification or shelving scheme |
Dewey Decimal Classification |